Skip to main content

Advertisement

SpringerLink
Log in

Management of Angina Post Percutaneous Coronary Intervention

  • Ischemic Heart Disease (D Mukherjee, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Our review discusses the management of post percutaneous coronary intervention angina (PPCIA) which negatively impacts 20–40% of patients and imposes a high burden on the healthcare system.

Recent Findings

Mechanisms of PPCIA include microvascular dysfunction, distal coronary vasospasm or disease, microembolization, myocardial bridge, coronary artery disease (CAD) progression, and rarely stent thrombosis or in-stent restenosis. Nitrates, beta blockers (BB), calcium channel blockers, and ranolazine are the common medical management options. Only BB showed 1-year mortality benefit following myocardial infarction. Stress echocardiography and cardiac magnetic resonance are the best to detect CAD vs. microvascular dysfunction. Invasively, vasoprovocative testing and fractional flow reserve provide useful prognostic information. If the ischemia burden is ≤10%, conservative management should be considered based upon the individual patient scenario.

Summary

The optimal management of PPCIA remains unclear and further research is necessary. Multiple treatment options exist, which should be implemented in an individualized fashion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular b-blockers, calcium antagonists, and mortality in stable coronary artery disease 1407 Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354–471. https://doi.org/10.1016/j.jacc.2012.07.013.

    Article  PubMed  Google Scholar 

  2. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949–3003. https://doi.org/10.1093/eurheartj/eht296.

    Article  PubMed  Google Scholar 

  3. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with Non-ST-Elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139–228. https://doi.org/10.1016/j.jacc.2014.09.017.

    Article  PubMed  Google Scholar 

  4. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;39(2):119–77 https://doi.org/10.1093/eurheartj/ehx393, accessed 17 Jan 2020

    Article  Google Scholar 

  5. • Crea F, Bairey Merz CN, Beltrame JF, Berry C, Camici PG, Kaski JC, et al. Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization. Eur Heart J. 2019;40(29):2455–62. https://doi.org/10.1093/eurheartj/ehy857 Mechanistic and summary paper of PPCIA.

    Article  PubMed  Google Scholar 

  6. • Niccoli G, Montone RA, Lanza GA, Crea F. Angina after percutaneous coronary intervention: the need for precision medicine. Int J Cardiol. 2017;248:14–9. https://doi.org/10.1016/j.ijcard.2017.07.105 Update on the diagnostic modalities for PPCIA.

    Article  PubMed  Google Scholar 

  7. Venkitachalam L, Kip KE, Mulukutla SR, Selzer F, Laskey W, Slater J, et al. NHLBI-Sponsored Dynamic Registry Investigators. Temporal trends in patient-reported angina at 1 year after percutaneous coronary revascularization in the stent era: a report from the National Heart, Lung, and Blood Institute sponsored 1997–2006 dynamic registry. Circ Cardiovasc Qual Outcomes. 2009;2:607–15. https://doi.org/10.1161/CIRCOUTCOMES.109.869131.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359:677–87. https://doi.org/10.1056/NEJMoa072771.

    Article  CAS  PubMed  Google Scholar 

  9. Gaglia MA Jr, Torguson R, Lipinski MJ, Gai J, Koifman E, Kiramijyan S, et al. Frequency of angina pectoris after percutaneous coronary intervention and the effect of metallic stent type. Am J Cardiol. 2016;117:526–31. https://doi.org/10.1016/j.amjcard.2015.11.036.

    Article  PubMed  Google Scholar 

  10. Grodzinsky A, Kosiborod M, Tang F, Jones PG, McGuire DK, Spertus JA, et al. Residual angina after elective percutaneous coronary intervention in patients with diabetes mellitus. Circulation: Cardiovascular Quality and Outcomes. 2017 Sep;10(9):e003553. https://doi.org/10.1161/CIRCOUTCOMES.117.003553.

    Article  Google Scholar 

  11. Pijls NH, Fearon WF, Tonino PA, Siebert U, Ikeno F, Bornschein B, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol. 2010;56:177–84. https://doi.org/10.1016/j.jacc.2010.04.012.

    Article  PubMed  Google Scholar 

  12. Ntalianis A, Sels JW, Davidavicius G, Tanaka N, Muller O, Trana C, et al. Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. JACC Cardiovasc Interv. 2010;3:1274–81. https://doi.org/10.1016/j.jcin.2010.08.025.

    Article  PubMed  Google Scholar 

  13. Al-Lamee R, Howard JP, Shun-Shin MJ, Thompson D, Dehbi HM, Sen S, et al. Fractional flow reserve and instantaneous wave-free ratio as predictors of the placebo-controlled response to percutaneous coronary intervention in stable single-vessel coronary artery disease. Circulation. 2018;138:1780–92. https://doi.org/10.1161/CIRCULATIONAHA.118.033801.

    Article  PubMed  Google Scholar 

  14. Ben-Yehuda O, Kazi DS, Bonafede M, Wade SW, Machacz SF, Stephens LA, et al. Angina and associated healthcare costs following percutaneous coronary intervention: a real-world analysis from a multi-payer database. Catheter Cardiovasc Interv. 2016 Dec;88(7):1017–24.

    Article  Google Scholar 

  15. Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. Eur Heart J. 2013 Dec 23;35(17):1101–11. https://doi.org/10.1093/eurheartj/eht513.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Gregorini L, Fajadet J, Robert G, Cassagneau B, Bernis M, Marco J. Coronary vasoconstriction after percutaneous transluminal coronary angioplasty is attenuated by antiadrenergic agents. Circulation. 1994;90:895–907. https://doi.org/10.1161/01.CIR.90.2.895.

    Article  CAS  PubMed  Google Scholar 

  17. Selvanayagam JB, Cheng AS, Jerosch-Herold M, Rahimi K, Porto I, van Gaal W, et al. Effect of distal embolization on myocardial perfusion reserve after percutaneous coronary intervention: a quantitative magnetic resonance perfusion study. Circulation. 2007;116:1458–64. https://doi.org/10.1161/CIRCULATIONAHA.106.671909.

    Article  PubMed  Google Scholar 

  18. Jackson LR, Zettler M, Peterson E, Ju C, Effron M, Messenger J, et al. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. JACC Cardiovasc Interv. 2015;8(14):1880–9. https://doi.org/10.1016/j.jcin.2015.08.018.

    Article  PubMed  Google Scholar 

  19. Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gru¨ntzig Lecture ESC 2014. Eur Heart J. 2015;36:3320–31. https://doi.org/10.1093/eurheartj/ehv511.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Thadani U, Fung HL, Darke AC, Parker JO. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose-response relation during acute and sustained therapy. Am J Cardiol. 1982;49:411–9. https://doi.org/10.1016/0002-9149(82)90518-5.

    Article  CAS  PubMed  Google Scholar 

  21. Wallace WA, Wellington KL, Chess MA, Liang CS. Comparison of nifedipine gastrointestinal therapeutic system and atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris. Am J Cardiol. 1994;73:23–8. https://doi.org/10.1016/0002-9149(94)90721-8.

    Article  CAS  PubMed  Google Scholar 

  22. van de Ven LL, Vermeulen A, Tans JG, Tans AC, Liem KL, Lageweg NC, et al. Which drug to choose for stable angina pectoris: a comparative study between bisoprolol and nitrates. Int J Cardiol. 1995;47:217–23. https://doi.org/10.1016/0167-5273(94)02194-N.

    Article  PubMed  Google Scholar 

  23. Steffensen R, Grande P, Pedersen F, Haunso S. Effects of atenolol and diltiazem on exercise tolerance and ambulatory ischaemia. Int J Cardiol. 1993;40:143–53. https://doi.org/10.1016/0167-5273(93)90277-N.

    Article  CAS  PubMed  Google Scholar 

  24. Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J. 1996;17:96–103. https://doi.org/10.1093/oxfordjournals.eurheartj.a014699.

    Article  CAS  PubMed  Google Scholar 

  25. de Vries RJ, van den Heuvel AF, Lok DJ, Claessens RJ, Bernink PJ, Pasteuning WH, et al. Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The Netherlands Working Group on Cardiovascular Research (WCN). Int J Cardiol. 1996;57:143–50. https://doi.org/10.1016/S0167-5273(96)02806-9.

    Article  PubMed  Google Scholar 

  26. Kawanishi DT, Reid CL, Morrison EC, Rahimtoola SH. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a doubleblind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol. 1992;19:409–17. https://doi.org/10.1016/0735-1097(92)90499-D.

    Article  CAS  PubMed  Google Scholar 

  27. Meyer TE, Adnams C, Commerford P. Comparison of the efficacy of atenolol and its combination with slow-release nifedipine in chronic stable angina. Cardiovasc Drugs Ther. 1993;7:909–13. https://doi.org/10.1007/BF00877726.

    Article  CAS  PubMed  Google Scholar 

  28. Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J. 1996;17:76–81. https://doi.org/10.1093/oxfordjournals.eurheartj.a014695.

    Article  CAS  PubMed  Google Scholar 

  29. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. Lancet. 2004;364:849–57. https://doi.org/10.1016/S0140-6736(04)16980-8.

    Article  CAS  PubMed  Google Scholar 

  30. Frishman WH, Glasser S, Stone P, Deedwania PC, Johnson M, Fakouhi TD. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol. 1999;83:507–14. https://doi.org/10.1016/S0002-9149(98)00904-7.

    Article  CAS  PubMed  Google Scholar 

  31. Morrow DA, Scirica BM, Chaitman BR, McGuire DK, Murphy SA, Karwatowska-Prokopczuk E, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119:2032–9. https://doi.org/10.1161/CIRCULATIONAHA.107.763912.

    Article  CAS  PubMed  Google Scholar 

  32. Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, et al. Evaluation of Ranolazine in Patients with Type 2 Diabetes Mellitus and Chronic Stable Angina. Results from the TERISA randomized clinical trial. J Am Coll Cardiol. 2013;61(20):2038–45. https://doi.org/10.1016/j.jacc.2013.02.011.

    Article  CAS  PubMed  Google Scholar 

  33. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775–83. https://doi.org/10.1001/jama.297.16.1775.

    Article  CAS  PubMed  Google Scholar 

  34. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309–16. https://doi.org/10.1001/jama.291.3.309.

    Article  CAS  PubMed  Google Scholar 

  35. Sorbets E, Steg PG, Young R, Danchin N, Greenlaw N, Ford I, et al. β-Blockers, Calcium Antagonists, and Mortality in Stable Coronary Artery Disease: An International Cohort Study. Eur Heart J. 2019;40(18):1399–407. https://doi.org/10.1093/eurheartj/ehy811.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. Eur Heart J. 2013;35(17):1101–11. https://doi.org/10.1093/eurheartj/eht513.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation. 2010 Jun 1;121(21):2317–25. https://doi.org/10.1161/CIRCULATIONAHA.109.900191.

    Article  PubMed  Google Scholar 

  38. Neglia D, Rovai D, Caselli C, Pietila M, Teresinska A, Aguade’-Bruix S, et al. Detection of significant coronary artery disease by noninvasive anatomical and functional imaging. Circ Cardiovasc Imaging. 2015;8:e002179. https://doi.org/10.1161/CIRCIMAGING.114.002179.

    Article  PubMed  Google Scholar 

  39. Picano E. The alternative “ischemic” cascade in coronary microvascular disease. Cardiologia. 1999;44:791–5.

    CAS  PubMed  Google Scholar 

  40. Thomson LE, Wei J, Agarwal M, Haft-Baradaran A, Shufelt C, Mehta PK, et al. Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction. A National Heart, Lung, and Blood Institute-sponsored study from the Women’s Ischemia Syndrome Evaluation. Circ Cardiovasc Imaging. 2015;8:e002481. https://doi.org/10.1161/CIRCIMAGING.114.002481.

    Article  PubMed  Google Scholar 

  41. Liu A, Wijesurendra RS, Liu JM, Forfar JC, Channon KM, Jerosch-Herold M, et al. Diagnosis of microvascular angina using cardiac magnetic resonance. J Am Coll Cardiol. 2018;71:969–79. https://doi.org/10.1016/j.jacc.2017.12.046.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Lanza GA, Camici PG, Galiuto L, Niccoli G, Pizzi C, Di Monaco A, et al. Methods to investigate coronary microvascular function in clinical practice. J Cardiovasc Med. 2013;14(1):1–8. https://doi.org/10.2459/JCM.0b013e328351680f.

    Article  Google Scholar 

  43. Ong P, Athanasiadis A, Perne A, Mahrholdt H, Schäufele T, Hill S, et al. Coronary vasomotor abnormalities in patients with stable angina after successful stent implantation but without in-stent restenosis. Clin Res Cardiol. 2014;103:11–9. https://doi.org/10.1007/s00392-013-0615-9.

    Article  PubMed  Google Scholar 

  44. Ford TJ, Stanley B, Good R, Rocchiccioli P, McEntegart M, Watkins S, et al. Stratified medical therapy using invasive coronary function testing in angina: CorMicA trial. J Am Coll Cardiol. 2018;72:2841–55. https://doi.org/10.1016/j.jacc.2018.09.006.

    Article  PubMed  Google Scholar 

  45. van Bommel RJ, Masdjedi K, Diletti R, Lemmert ME, van Zandvoort L, Wilschut J, et al. Routine Fractional Flow Reserve Measurement After Percutaneous Coronary Intervention: The FFR-SEARCH Study. Circulation: Cardiovascular Interventions. 2019;12(5):e007428. https://doi.org/10.1161/CIRCINTERVENTIONS.118.007428.

    Article  Google Scholar 

  46. • Fournier S, Ciccarelli G, Toth GG, Milkas A, Xaplanteris P, Tonino PA, et al. Association of Improvement in Fractional Flow Reserve With Outcomes, Including Symptomatic Relief, After Percutaneous Coronary Intervention. JAMA Cardiol. 2019;4(4):370–4. https://doi.org/10.1001/jamacardio.2019.0175 The larger the improvement in FFR, the larger the symptomatic relief from angina and lower event rate.

    Article  PubMed  Google Scholar 

  47. Hakeem A, Uretsky BF. Role of Postintervention Fractional Flow Reserve to Improve Procedural and Clinical Outcomes. Circulation. 2019;139(5):694–706.

    Article  Google Scholar 

  48. Mukherjee D. Management of refractory angina in the contemporary era. Eur Heart J. 2013;34(34):2655–7. https://doi.org/10.1093/eurheartj/eht190.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA

    Jose B. Cruz Rodriguez & Subrata Kar

Authors
  1. Jose B. Cruz Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Subrata Kar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Subrata Kar.

Ethics declarations

Conflict of Interest

Jose B. Cruz Rodriguez and Subrata Kar declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Ischemic Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cruz Rodriguez, J.B., Kar, S. Management of Angina Post Percutaneous Coronary Intervention. Curr Cardiol Rep 22, 7 (2020). https://doi.org/10.1007/s11886-020-1259-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-020-1259-9

Keywords

Search

Navigation